NCT05484622 2026-03-12
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
Servier
Phase 1 Active not recruiting
Clinical Trials
9 trialsNCT06809322 2026-02-17
VIGOR
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
NCT07235748 2026-02-17
Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants
Servier
Phase 1 Completed
NCT07240662 2026-01-09
VIOLETA
iOMEDICO AG
Recruiting
NCT07215910 2025-10-14
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Not yet recruiting
NCT05609994 2025-07-18
ViCToRy
Duke University
Phase 1 Recruiting
NCT06969352 2025-05-13
VICTORIA
Servier (Tianjin) Pharmaceutical Co. LTD.
Not yet recruiting
NCT04164901 2025-04-03
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
Servier
Phase 3 Active not recruiting
NCT05592743 2024-11-05
Vorasidenib Expanded Access Program
Servier
Approved for marketing